About Ally Bridge Group
Ally Bridge Group is a private equity firm founded in 2013. It is primarily based in Hong Kong, China. As of Apr 2026, Ally Bridge Group is an active investor with a portfolio of 92 companies, comprising 92 funding rounds and 1 acquisition. In the last 12 months, it has participated in 11 funding rounds. The firm primarily invests in companies based in United States and China. Its portfolio is spread across a wide range of sectors from Life Sciences to High Tech. Its latest investment was a $***** Series F round in Calyxo on Apr 01, 2026 which also saw participation from Janus Henderson Investors, Questa Capital and other investors.
A lot of funds co-invest with Ally Bridge Group, with names like Janus Henderson Investors sharing a substantial percentage of its portfolio.
Ally Bridge Group has a team of 35 people, including 6 partners.
Key Metrics
Ally Bridge Group's Portfolio
Ally Bridge Group has a portfolio of 92 companies. They have invested in a total of 92 companies. Their most recent investment was in Calyxo (Series F round) on Apr 01, 2026. Here is the most recent investment by Ally Bridge Group:Date | Company | Round | Amount | Co-Investors |
|---|---|---|---|---|
Apr 01, 2026 | Series F | 9339 | ||
Mar 13, 2026 | Series E | 2638 | ||
Jan 30, 2026 | Post IPO | 2938 | ||
Dec 30, 2025 | Series B | 6227 |
Ally Bridge Group has acquired 1 company. Their most recent acquisition was of Luoxin Pharmaceutical Group on Mar 16, 2017. Here is the most recent acquisition by Ally Bridge Group:
Acquisition Date | Company | Short Description | Total Funding | Founded Year |
|---|---|---|---|---|
Mar 16, 2017 | Developer and manufacturer of pharmaceutical products | $301M | 2006 |
Here is the portfolio snapshot of Ally Bridge Group:
Investments by Year
The maximum number of investments were made in 2021
Acquisitions by Year
The maximum number of acquisitions were made in 2017
Portfolio by Location
Companies are primarily in United States and China
Portfolio by Sector
Companies are primarily in Life Sciences
Team profile of Ally Bridge Group
Ally Bridge Group has a team of 35 members including 6 Partners and 7 Principals located in United States and China. Ally Bridge Group's team sits on the board of 2 companies.Here is a list of top team members in Ally Bridge Group:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Houston | - | ||
Partner | New York City | |||
Partner | New York City | - | ||
Partner | Hong Kong | - | ||
Partner | - | - | - | |
Principal | Hong Kong | - | ||
Principal | New York City | |||
Principal | New York City | - | ||
Principal | - | - | ||
Principal | Hong Kong | - |
Co-investors of Ally Bridge Group
Over the past 13 years, 243 investors have co-invested in Ally Bridge Group's portfolio companies.
- Top Co-investors of Ally Bridge Group: 243 investors entered a company along with Ally Bridge Group. These include investors like Janus Henderson Investors (10 companies).
Ally Bridge Group News
•
Calyxo Secures $40 Million Series F FinancingG-MedTech•Apr 14, 2026•Calyxo, Ally Bridge Group, Janus Henderson Investors, CRG and 4 others
•
Colorado biotech Ambrosia lands $100M for oral GLP-1Endpoints•Mar 31, 2026•Ambrosia Biosciences, Blue Owl, Deep Track Capital, Samsara BioCapital and 8 others
•
Imperative Care Raises $100M in FundingFinSMEs•Mar 18, 2026•Patient Square Capital, Imperative Care, Bain Capital Life Sciences, Perceptive Advisors and 7 others
•
Biobeat secures $50M Series B funding to fuel US expansion of its ABPM system.Refresh Miami•Jan 01, 2026•Ally Bridge Group, Patient Square Capital, Orbimed, Biobeat and 1 other
•
Solve Therapeutics Raises $120 Million to Develop Best-in-Class ADCs for Solid TumorsBusiness Wire•Nov 17, 2025•B Capital, Balyasny Asset Management, Ally Bridge Group, Alexandria and 10 others
•
•
Cybin Announces $175 Million Registered Direct OfferingBusiness Wire•Oct 28, 2025•Pivotal Life Sciences, Cybin, Stonepine, Adage Capital Management and 13 others
•
Ovid gets a boost from Phase 1 data, $81M+ PIPE financingEndpoints•Oct 03, 2025•Ovid Therapeutics, Leerink Partners, Eventide Asset Management, Blue Owl and 9 others
•
•
iBio Announces Pricing of $50 Million Public OfferingGlobeNewswire•Aug 19, 2025•iBio, Vestal Point Capital, SilverArc Capital, Adage Capital Management and 5 others
